*Others include "Compliance, "Patient's intolerability to previous treatment", "Easy to use", "Contraindications -SGLT-2/Renal insufficiency", "Unable to achieve disease control with previous treatment", "Patient's lifestyle", "Patient's wish", "Efficacy" and "Cost". † Others include "Lack of treatment adherence", "Comorbidities -dementia, psychiatric", "Dosage", "Needle phobia" and "Don't know/recall". GI, gastrointestinal; HbA1c, glycated hemoglobin; IDegLira, insulin degludec/liraglutide; SGLT-2, sodium/glucose cotransporter 2 
AE REPORTING STATEMENT
We are required to pass on details of adverse events, product complaints, pregnancies or other safety information that are reported during the course of this survey to the sponsor of this market research. Although what you say will, of course, be treated in confidence, should you raise during the discussion an adverse event, product complaint, pregnancy or other safety information, we will need to report this even if it has already been reported by you directly to the company or the regulatory authorities [for UK only: using the MHRA's 'Yellow Card' system]. In such a situation we need to know whether or not you are willing to waive the confidentiality given to you under the Market Research Codes of conduct specifically in relation to that adverse event, product complaint, pregnancy or other safety information.
Do you agree to waive the confidentiality given to you under the Market Research Codes of Conduct specifically in relation to any adverse event you report to us?
Waive confidentiality statement
If you agree to waive confidentiality, your name and contact details will be forwarded to the sponsor's pharmacovigilance department for the sole purpose of follow-up of such report(s). All other information that you give us in the context of this market research will continue to remain confidential. Are you willing to participate with the interview on this basis? □ I agree □ I do not agree [PN: IF SELECT I AGREE AT WAIVE CONFIDENTIALITY STATEMENT] Thank you. Please note that if you provide your name during the adverse event reporting, this will not be linked in any way to your responses given during the interview.
We are obligated to share the manner in which your personal information will be handled and stored. Any safety information we receive will be forwarded to the sponsor of this research for their records. The sponsor will record any safety information including personal data received in their global database in the interests of patient safety and in compliance with all applicable global laws and regulations; and During the reporting of safety information, the sponsor will not disclose such personal data to any unassociated third parties with the exception of any disclosures required by applicable law, regulation or the order of a competent authority Please can you confirm if you agree to your personal details being stored for this purpose?
□ I agree □ I do not agree [PN: IF SELECT I DO NOT AGREE AT WAVE CONFIDENTIALITY STATEMENT] If we become aware of a reportable adverse event we are obliged to report this to the pharmaceutical company. We will file this report without giving any of your details, but if the Drug Safety Department requires more information, may we contact you again (without identifying you to the pharmaceutical company)?
Introduction
Thank you for taking the time to reflect and comment on your experiences of treating patients with fixed combination of basal insulin/GLP-1 (IDegLira).
All answers that you provide will be treated in the strictest confidence and your identity will not be revealed to any third parties. The results from your interview will be aggregated with those provided by other respondents. The aggregated results may be used in publications by the survey sponsor.
Your answers will be treated as anonymous and confidential.
Please respond to the questions by ticking the answer that best reflects your experience. There are no right or wrong answers to any of these questions. 
Screener & Caseload Information
Please answer the below questions thinking about an "average" Type-2 Diabetes patient who has no major comorbidities, aged 35-70 years, with average cognitive ability/normal mental status, and BMI equal to 25 or higher.
5. What treatment(s) was the patient receiving prior to treatment with IDegLira? (Please tick all that apply)
. Other *Should you choose 'Other' as one of your answers, you will have a chance to specify that answer on the next screen.
Multiple responses possible If Q6_i7 selected then ask "Please specify the other treatment" 
